Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity-Reference-Cited by-同舟云学术

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity

Published:2022-07 Issue:7 Volume:40 Page:754-767.e6
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Elamin Yasir Y.^ORCID,Robichaux Jacqulyne P.,Carter Brett W.,Altan Mehmet,Tran Hai,Gibbons Don L.,Heeke Simon,Fossella Frank V.,Lam Vincent K.,Le Xiuning,Negrao Marcelo V.^ORCID,Nilsson Monique B.,Patel Anisha,Vijayan R.S.K.,Cross Jason B.,Zhang Jianjun^ORCID,Byers Lauren A.,Lu Charles,Cascone Tina^ORCID,Feng Lei,Luthra Rajyalakshmi,San Lucas Francis A.,Mantha Geeta,Routbort Mark,Blumenschein George,Tsao Anne S.,Heymach John V.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference61 articles.

1. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics;Arcila;Mol. Cancer Ther.,2013

2. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network;Beau-Faller;Ann. Oncol.,2014

3. Crystal structures of an archaeal thymidylate kinase from Sulfolobus tokodaii provide insights into the role of a conserved active site Arginine residue;Biswas;J. Struct. Biol.,2017

4. Molecular operating environment;Boyd;Chem. World,2005

5. Clinical outcomes of EGFR exon 20 insertion mutations in advanced non-small cell lung cancer in Korea;Byeon;Cancer Res. Treat.,2019

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the future: Innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy;European Journal of Medicinal Chemistry;2024-10

2. Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer;European Journal of Cancer;2024-09

3. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

4. Current clinical practice and physicians’ insights on Chinese patients with advanced non-small cell lung cancer habouring epidermal growth factor receptor 20 insertion mutation;BMC Cancer;2024-08-23

5. Molecular heterogeneity and treatment outcome of EGFR exon 20 insertion mutations in Chinese patients with advanced non-small cell lung cancer: insights from a large-scale real-world study;BMC Cancer;2024-08-14